MA29524B1 - Anticorps diriges contre la myostatine - Google Patents

Anticorps diriges contre la myostatine

Info

Publication number
MA29524B1
MA29524B1 MA30410A MA30410A MA29524B1 MA 29524 B1 MA29524 B1 MA 29524B1 MA 30410 A MA30410 A MA 30410A MA 30410 A MA30410 A MA 30410A MA 29524 B1 MA29524 B1 MA 29524B1
Authority
MA
Morocco
Prior art keywords
myostatin
antibodies
human antibodies
relates
directed against
Prior art date
Application number
MA30410A
Other languages
English (en)
Inventor
Eva Rose Chin
Chikwendu Ibebunjo
Philip Albert Krasney
Junming Yie
Joseph Zachwieja
Larry Green
Original Assignee
Pfizer
Amgen Fremont Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Amgen Fremont Inc filed Critical Pfizer
Publication of MA29524B1 publication Critical patent/MA29524B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des anticorps parmi lesquels figurent des anticorps humains, et des parties de liaison à l'antigène correspondantes, qui se lient à la myostatine, et dont la fonction est d'inhiber la myostatine. L'invention concerne également des anticorps humains dirigés contre la myostatine, ainsi que des parties de liaison à l'antigène correspondantes. Cette invention se rapporte aussi à des anticorps qui sont chimériques, bispécifiques, dérivatisés, monocaténaires, ou qui se présentent sous la forme de parties de protéines de fusion. L'invention concerne par ailleurs des immunoglobulines isolées à chaîne lourde et à chaîne légère qui sont dérivées d'anticorps humains dirigés contre la myostatine, et des molécules codant ces immunoglobulines. L'invention concerne en outre des procédés pour produire des anticorps humains dirigés contre la myostatine, des compositions contenant des anticorps, et des procédés d'utilisation de ces anticorps et de ces compositions à des fins de diagnostic et de traitement. L'invention concerne également des procédés de thérapie génique faisant appel à des molécules d'acide nucléique codant les molécules d'immunoglobuline à chaîne lourde et/ou à chaîne légère qui comprennent les anticorps humains dirigés contre la myostatine. La présente invention concerne également des animaux ou des plantes transgéniques comprenant les molécules d'acide nucléique selon l'invention.
MA30410A 2005-04-25 2007-11-22 Anticorps diriges contre la myostatine MA29524B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67493305P 2005-04-25 2005-04-25

Publications (1)

Publication Number Publication Date
MA29524B1 true MA29524B1 (fr) 2008-06-02

Family

ID=37215358

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30410A MA29524B1 (fr) 2005-04-25 2007-11-22 Anticorps diriges contre la myostatine

Country Status (23)

Country Link
US (2) US7807159B2 (fr)
EP (2) EP1877075A4 (fr)
JP (1) JP2008539241A (fr)
KR (1) KR20080011403A (fr)
CN (1) CN101272802A (fr)
AP (1) AP2007004243A0 (fr)
AR (1) AR053067A1 (fr)
AU (1) AU2006239860B2 (fr)
BR (1) BRPI0610248A2 (fr)
CA (1) CA2605723A1 (fr)
CR (1) CR9466A (fr)
DO (1) DOP2006000093A (fr)
EA (2) EA201100642A1 (fr)
IL (1) IL186739A (fr)
MA (1) MA29524B1 (fr)
MX (1) MX2007013217A (fr)
NL (3) NL1031674C2 (fr)
NO (1) NO20076061L (fr)
PE (1) PE20061395A1 (fr)
TN (1) TNSN07394A1 (fr)
TW (1) TW200724548A (fr)
WO (1) WO2006116269A2 (fr)
ZA (1) ZA200709291B (fr)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1855694B1 (fr) 2005-02-09 2020-12-02 Sarepta Therapeutics, Inc. Composition antisens permettant de traiter une atrophie musculaire
EP1951756B1 (fr) 2005-10-06 2015-01-07 Eli Lilly And Company Anticorps anti-myostatine
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
ES2649983T3 (es) 2005-11-23 2018-01-16 Acceleron Pharma, Inc. Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo
BRPI0620316A2 (pt) * 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
BRPI0716249A2 (pt) * 2006-09-05 2013-09-03 Lilly Co Eli anticorpos antimiostatina
AU2012265564B2 (en) * 2006-09-08 2016-05-26 Amgen Inc Anti-activin A antibodies and uses thereof
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
EP1997830A1 (fr) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. Molécules à liaison spécifiques RSV et leur moyen de fabrication
HUE055524T2 (hu) 2007-06-01 2021-11-29 Wyeth Llc A bcrabl génben 1457T>C mutációt tartalmazó, imatinibbel szemben ellenálló krónikus mielogén leukémia kezelése bozutinib vegyület alkalmazásával
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CA2685540C (fr) 2007-08-03 2018-10-16 Graham Michael Wynne Combinaisons de medicaments pour le traitement de la dystrophie musculaire de duchenne
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
KR101759457B1 (ko) * 2007-12-21 2017-07-31 메디뮨 리미티드 인터루킨-4 수용체 알파(ＩＬ-4Ｒα)에 대한 결합 구성원-173
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
TW201006485A (en) 2008-06-03 2010-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2726087A1 (fr) 2008-06-03 2009-12-10 Tariq Ghayur Immunoglobulines a deux domaines variables et leurs utilisations
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
AU2009294415B2 (en) 2008-09-19 2015-09-24 Medimmune Llc Antibodies directed to DLL4 and uses thereof
WO2010080463A1 (fr) * 2008-12-18 2010-07-15 Imclone Llc Humanisation d'anticorps
UY32341A (es) * 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
TWI541021B (zh) 2009-03-05 2016-07-11 艾伯維有限公司 Ｉｌ－１７結合蛋白
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP3332796A1 (fr) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Protéines actriib et variants et leurs utilisations se rapportant à l'induction de l'utrophine pour une thérapie de la dystrophie musculaire
AR081246A1 (es) 2010-05-14 2012-07-18 Abbott Lab Proteinas de union a il-1
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
EP3252072A3 (fr) 2010-08-03 2018-03-14 AbbVie Inc. Immunoglobuline à double domaine variable et ses utilisations
SG187867A1 (en) 2010-08-16 2013-03-28 Amgen Inc Antibodies that bind myostatin, compositions and methods
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
EP2625189B1 (fr) 2010-10-01 2018-06-27 ModernaTX, Inc. Synthèse d'acides nucléiques et méthodes d'utilisation associées
EP2647706B1 (fr) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l'antigène, apte à se lier de façon répétée à une pluralité de molécules d'antigène
US10920242B2 (en) 2011-02-25 2021-02-16 Recombinetics, Inc. Non-meiotic allele introgression
US9528124B2 (en) 2013-08-27 2016-12-27 Recombinetics, Inc. Efficient non-meiotic allele introgression
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
DK2780368T3 (en) 2011-11-14 2018-02-05 Regeneron Pharma COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
KR101704893B1 (ko) * 2012-06-15 2017-02-08 화이자 인코포레이티드 Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
US9873739B2 (en) 2012-08-01 2018-01-23 Ikaika Therapeutics, Llc Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (LTBP4)
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
TWI606063B (zh) * 2012-08-23 2017-11-21 艾澤西公司 結合至１５８ｐ１ｄ７蛋白之抗體藥物結合物（ａｄｃ）
WO2014030750A1 (fr) 2012-08-24 2014-02-27 中外製薬株式会社 ANTICORPS Fc SPÉCIFIQUE À FcyRII DE SOURIS
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
ES2984405T3 (es) 2012-09-13 2024-10-29 Bristol Myers Squibb Co Proteínas de dominio de andamio basadas en fibronectina que se unen a la miostatina
TW202037609A (zh) 2012-11-01 2020-10-16 美商艾伯維有限公司 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
AU2014212014A1 (en) 2013-02-01 2015-08-27 Amgen Inc. Administration of an anti-activin-A compound to a subject
CN103145836A (zh) * 2013-02-07 2013-06-12 浙江大学 抗肌抑素单链抗体及其编码基因、表达载体、重组转化子和应用
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
WO2014144280A2 (fr) 2013-03-15 2014-09-18 Abbvie Inc. Protéines de liaison spécifiques à domaines variables doubles dirigées contre il -1β et/ou il -17
CN105246914B (zh) 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
ES2924479T3 (es) 2013-04-08 2022-10-07 Harvard College Composiciones para rejuvenecer las células madre del músculo esquelético
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
US20160220640A1 (en) * 2013-06-11 2016-08-04 The Brigham And Women's Hospital, Inc. Methods and compositions for increasing neurogenesis and angiogenesis
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
EP3041863A4 (fr) 2013-09-05 2017-08-16 Amgen Inc. Molécules contenant des fc et présentant des profils de glycoforme prévisibles, uniformes et reproductibles
JP2017509647A (ja) * 2014-03-21 2017-04-06 アクセルロン ファーマ， インコーポレイテッド アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法
TW201622746A (zh) * 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
US10156562B2 (en) 2014-05-16 2018-12-18 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
EP3215175A4 (fr) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anticorps anti-pro-myostatine/myostatine latente et leurs utilisations
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
EP3280442A4 (fr) * 2015-04-08 2018-10-31 Sorrento Therapeutics, Inc. Agents thérapeutiques de type anticorps se liant à cd123
US10100118B2 (en) 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
KR20170135967A (ko) 2015-04-15 2017-12-08 리제너론 파마슈티칼스 인코포레이티드 Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
JP6664129B2 (ja) * 2015-09-10 2020-03-13 学校法人慶應義塾 筋萎縮の予防剤及び／又は治療剤のスクリーニング方法
HRP20211081T1 (hr) * 2015-09-15 2021-10-15 Scholar Rock, Inc. Anti-pro/latentna miostatinska protutijela i njihove uporabe
EP3858993A1 (fr) 2015-10-09 2021-08-04 Sarepta Therapeutics, Inc. Compositions et procédés pour le traitement de la dystrophie musculaire de duchenne et de troubles apparentés
AR107078A1 (es) 2015-12-18 2018-03-21 Chugai Pharmaceutical Co Ltd Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
WO2017110981A1 (fr) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-myostatine et procédés d'utilisation
CA3010799A1 (fr) 2016-01-06 2017-07-13 President And Fellows Of Harvard College Un traitement par le gdf11 previent la prise de poids, ameliore la tolerance au glucose, et diminue la steatose hepatique
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
RU2613420C1 (ru) * 2016-04-13 2017-03-16 Сергей Михайлович Юдин Рекомбинантный белок Мио-ГСД, способ его получения, инъекционный препарат для повышения мышечной массы сельскохозяйственных животных, птицы и животных семейства псовых, а также способ использования препарата
NZ789269A (en) 2016-06-13 2026-01-30 Scholar Rock Inc Use of myostatin inhibitors and combination therapies
KR102376582B1 (ko) 2016-06-17 2022-03-18 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체 및 사용 방법
EP3494991A4 (fr) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Composition pour la prophylaxie ou le traitement de maladies liées à il-8
AU2017381585B2 (en) * 2016-12-19 2025-02-13 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Antibodies against LIF and uses thereof
EP4218817A3 (fr) * 2017-01-06 2023-09-06 Scholar Rock, Inc. Méthodes de traitement de maladies métaboliques par inhibition de l'activation de la myostatine
CA3056011A1 (fr) 2017-03-14 2018-09-20 Amgen Inc. Controle des glycoformes afucosylees totales d'anticorps produits en culture cellulaire
MX2020008991A (es) 2018-03-01 2020-12-10 Regeneron Pharma Metodos para alterar la composicion corporal.
US12325737B2 (en) 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
PT3773713T (pt) 2018-04-06 2025-07-29 Regeneron Pharma Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia
KR20210104744A (ko) 2018-12-18 2021-08-25 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체, gdf8 및 액티빈 a에 대한 길항제를 사용하여 체중 및 제지방 근육량을 향상시키기 위한 조성물 및 방법
WO2020132647A1 (fr) 2018-12-21 2020-06-25 Northwestern University Utilisation d'annexines dans la prévention et le traitement d'une lésion de la membrane musculaire
WO2020139977A1 (fr) 2018-12-26 2020-07-02 Northwestern University Utilisation de stéroïdes de glucocorticoïdes dans la prévention et le traitement de l'atrophie musculaire, du vieillissement et du trouble métabolique
MX2021010857A (es) 2019-03-11 2021-12-15 Janssen Biotech Inc Anticuerpos biespecificos anti-v(beta17)/anti-cd123.
BR112022005583A2 (pt) 2019-09-26 2022-09-20 Amgen Inc Métodos para a produção de composições de anticorpos
RU2750267C1 (ru) * 2020-02-07 2021-06-25 Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ» Рекомбинантный ростовой дифференцировочный фактор роста 11 (GDF11), способ его получения, инъекционный препарат для повышения мышечной массы млекопитающих животных и птицы, а также способ использования препарата
CN111549030A (zh) * 2020-05-26 2020-08-18 上海海洋大学 一种鲫鱼肌间刺变粗的分子育种方法
CN111500581A (zh) * 2020-05-26 2020-08-07 上海海洋大学 一种鲢鱼和鳙鱼肌间刺变粗的分子育种方法
CN111560401A (zh) * 2020-05-26 2020-08-21 上海海洋大学 一种翘嘴红鲌和团头鲂肌间刺变粗的分子育种方法
CN111549031A (zh) * 2020-05-26 2020-08-18 上海海洋大学 一种草鱼和青鱼肌间刺变粗的分子育种方法
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
WO2022056197A1 (fr) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Molécules de ciblage immunitaire et leurs utilisations
TW202227495A (zh) 2020-09-11 2022-07-16 美商健生生物科技公司 用於調節β鏈介導之免疫的方法及組成物
US20220089737A1 (en) * 2020-09-11 2022-03-24 Janssen Biotech, Inc. Multi-specific immune targeting molecules and uses thereof
KR20230087539A (ko) 2020-10-15 2023-06-16 암젠 인크 항체 생산 방법에서의 상대적인 비결합 글리칸
GB2636643B (en) * 2020-12-03 2026-03-11 Lart Bio Co Ltd Transgenic animal having modified myostatin gene
KR20240006505A (ko) * 2021-03-12 2024-01-15 이칸 스쿨 오브 메디슨 엣 마운트 시나이 Bk 바이러스에 대한 중화 단클론성 항체
EP4352094A1 (fr) 2021-06-07 2024-04-17 Amgen Inc. Utilisation de fucosidase pour contrôler le taux d'afucosylation de protéines glycosylées
US20250076309A1 (en) 2021-10-05 2025-03-06 Amgen Inc. Fc-gamma receptor ii binding and glycan content
CN114891101B (zh) * 2021-12-02 2023-06-16 吉林省农业科学院 一种牛肌肉生长抑制素蛋白单克隆抗体及其应用
KR20250035503A (ko) * 2022-03-31 2025-03-12 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 인간 Siglec-9에 대한 항체 및 이의 면역요법을 위한 용도
WO2023215725A1 (fr) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire
WO2024064842A1 (fr) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Méthodes de traitement de l'obésité, du diabète et de la dysfonction hépatique
CN115951044B (zh) * 2022-12-02 2025-02-18 北京世纪沃德生物科技有限公司 基于胶乳免疫比浊法测定s100a8/9的试剂盒及方法
EP4638496A1 (fr) 2022-12-22 2025-10-29 Scholar Rock, Inc. Anticorps inhibiteurs sélectifs et puissants de l'activation de la myostatine
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025038600A1 (fr) 2023-08-14 2025-02-20 Amgen Inc. Procédés de réduction de couleur jaune
WO2025101820A1 (fr) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) * 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
EP0216846B2 (fr) 1985-04-01 1995-04-26 Celltech Limited Lignee cellulaire de myelomes transformee et procede d'expression d'un gene codant un polypeptide eucaryotique employant cette lignee
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) * 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) * 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5959177A (en) * 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
WO1996033735A1 (fr) 1995-04-27 1996-10-31 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133557D1 (de) * 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
CA2095633C (fr) 1990-12-03 2003-02-04 Lisa J. Garrard Methode d'enrichissement de proteines variantes aux proprietes liantes alterees
EP1820858B1 (fr) 1991-03-01 2009-08-12 Dyax Corporation Protéine chimère comprenant des micro-protéines dotées de deux liaisons disulfure ou plus et ses modes de réalisation
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993004169A1 (fr) 1991-08-20 1993-03-04 Genpharm International, Inc. Ciblage de genes dans des cellules animales au moyen de produits de synthese d'adn isogeniques
EP0605522B1 (fr) 1991-09-23 1999-06-23 Medical Research Council Méthodes de production d'anticorps humanisés
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
WO1994019935A1 (fr) 1993-03-09 1994-09-15 Genzyme Corporation Isolement de constituants d'interet du lait
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
US6091001A (en) * 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
AU705616B2 (en) * 1995-04-21 1999-05-27 Cell Genesys, Inc. Generation of large genomic DNA deletions
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US5916771A (en) * 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (fr) 1996-12-03 2015-02-03 Amgen Fremont Inc. Anticorps humains qui se lient au tnf.alpha.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP0983303B1 (fr) 1997-05-21 2006-03-08 Biovation Limited Procede de production de proteines non immunogenes
AU2978899A (en) 1998-03-03 1999-09-20 Abgenix, Inc. Cd147 binding molecules as therapeutics
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
EP1105427A2 (fr) 1998-08-17 2001-06-13 Abgenix, Inc. Production de molecules modifiees avec demi-vie serique prolongee
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
CZ302706B6 (cs) 1998-12-23 2011-09-14 Pfizer Inc. Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
WO2003048327A2 (fr) * 2001-12-03 2003-06-12 Abgenix, Inc. Anticorps anti-cd45rb s'utilisant dans le traitement de maladies auto-immunes et de rejet de greffon
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
RU2322261C2 (ru) * 2003-06-02 2008-04-20 Уайт Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
EP3006039B1 (fr) * 2004-03-02 2021-01-06 Acceleron Pharma Inc. Alk7 polypeptides pour stimuler la perte de graisse
ATE557042T1 (de) * 2004-03-23 2012-05-15 Lilly Co Eli Anti-myostatin-antikörper

Also Published As

Publication number Publication date
EP2295466A3 (fr) 2011-08-17
IL186739A0 (en) 2008-02-09
MX2007013217A (es) 2008-03-11
CN101272802A (zh) 2008-09-24
ZA200709291B (en) 2009-01-28
EP1877075A2 (fr) 2008-01-16
WO2006116269A2 (fr) 2006-11-02
NO20076061L (no) 2007-11-26
DOP2006000093A (es) 2007-01-31
AP2007004243A0 (en) 2007-12-31
TW200724548A (en) 2007-07-01
NL1033650C2 (nl) 2009-01-12
AR053067A1 (es) 2007-04-18
EA015534B1 (ru) 2011-08-30
NL2002255C2 (nl) 2009-09-24
KR20080011403A (ko) 2008-02-04
NL2002255A1 (nl) 2009-03-26
AU2006239860B2 (en) 2012-01-19
EP1877075A4 (fr) 2008-07-30
EA201100642A1 (ru) 2011-12-30
AU2006239860A1 (en) 2006-11-02
BRPI0610248A2 (pt) 2010-06-08
JP2008539241A (ja) 2008-11-13
IL186739A (en) 2012-12-31
US20060263354A1 (en) 2006-11-23
CR9466A (es) 2008-02-13
WO2006116269A3 (fr) 2007-03-01
NL1033650A1 (nl) 2007-05-16
PE20061395A1 (es) 2007-01-15
US7807159B2 (en) 2010-10-05
NL1031674C2 (nl) 2007-04-26
CA2605723A1 (fr) 2006-11-02
EP2295466A2 (fr) 2011-03-16
US20110091455A1 (en) 2011-04-21
TNSN07394A1 (en) 2009-03-17
NL1031674A1 (nl) 2006-10-27
EA200702327A1 (ru) 2008-04-28

Similar Documents

Publication Publication Date Title
MA29524B1 (fr) Anticorps diriges contre la myostatine
WO2008019290A3 (fr) Anticorps anti-erbb2
MY140862A (en) ANTIBODIES TO MAdCAM
MA28092A1 (fr) Anticorps diriges contre un m-csf
AP1918A (en) Antibodies to CD40
MA29991B1 (fr) Anticorps contre la p-cadherine
AP2072A (en) Antibodies to insulin-like growth factor I receptor
WO2008060331A3 (fr) Anticorps au coronavirus sras
AU2003220525A1 (en) Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
MA48241A1 (fr) Anticorps dirigés contre madcam
TNSN02089A1 (fr) Anticorps a cd40